Acquist Therapeutics, Inc. is developing innovative drugs for inflammatory diseases. Our work derives from published data using a drug that was tested in > 350 U.S. subjects. The Acquist chemistry program synthesized 140 small molecule derivatives that are uniquely bispecific, safer, orally absorbed, and highly potent.
These drugs target uric acid, an established inflammasome activator; our initial clinical target is gout. The gout market is expected to grow at a CAGR of 15-17% from 2019-2027, with global revenue of $8-9BN by 2027. The Company envisions clinical testing of additional discrete compounds in chronic kidney disease and NASH.
Our clinical lead, ACQT1127, has completed non-GLP tox (rat/monkey), and GLP studies will complete Q4 2020. Manufacturing has scaled to 2.5 kg. Four global patents have issued with composition coverage to 2039. We anticipate IND filing in H1 2021. We are seeking investors for a Series A round, along with potential pharma partners.
These drugs target uric acid, an established inflammasome activator; our initial clinical target is gout. The gout market is expected to grow at a CAGR of 15-17% from 2019-2027, with global revenue of $8-9BN by 2027. The Company envisions clinical testing of additional discrete compounds in chronic kidney disease and NASH.
Our clinical lead, ACQT1127, has completed non-GLP tox (rat/monkey), and GLP studies will complete Q4 2020. Manufacturing has scaled to 2.5 kg. Four global patents have issued with composition coverage to 2039. We anticipate IND filing in H1 2021. We are seeking investors for a Series A round, along with potential pharma partners.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Inflammation
Lead Product in Development:
ACQT1127
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
One
Speaker
